Upstream / Downstream
Explore pathways related to this product.
CST Antibody Performance Guarantee
Find answers on our FAQs page.
PTM information and tools available.
Mono-Methyl-Histone H3 (Lys9) Antibody #7538
This product is discontinued
Mono-Methyl-Histone H3 (Lys9) Antibody specificity was determined by peptide ELISA. The graph depicts the binding of the antibody to precoated mono-methyl-histone H3 (Lys9) peptide in the presence of increasing concentrations of various competitor peptides. As shown, only the mono-methyl-histone H3 (Lys9) peptide competed away binding of the antibody.Learn more about how we get our images
Gallery: Mono-Methyl-Histone H3 (Lys9) Antibody #7538
Mono-Methyl-Histone H3 (Lys9) Antibody recognizes endogenous levels of histone H3 protein only when mono-methylated at Lys9. The antibody does not cross-react with non-methylated, di-methylated, or tri-methylated histone H3 Lys9. In addition, the antibody does not cross-react with histone H3 mono-methylated at Lys4, Lys27, Lys36, or Lys79.Species predicted to react based on 100% sequence homology: Xenopus, Zebrafish, Pig, S. cerevisiae, Horse
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding mono-methyl Lys9 of human histone H3 protein. Antibodies are purified by protein A and peptide affinity chromatography.
The nucleosome, made up of four core histone proteins (H2A, H2B, H3, and H4), is the primary building block of chromatin. Originally thought to function as a static scaffold for DNA packaging, histones have now been shown to be dynamic proteins, undergoing multiple types of post-translational modifications, including acetylation, phosphorylation, methylation, and ubiquitination (1). Histone methylation is a major determinant for the formation of active and inactive regions of the genome and is crucial for the proper programming of the genome during development (2,3). Arginine methylation of histones H3 (Arg2, 17, 26) and H4 (Arg3) promotes transcriptional activation and is mediated by a family of protein arginine methyltransferases (PRMTs), including the co-activators PRMT1 and CARM1 (PRMT4) (4). In contrast, a more diverse set of histone lysine methyltransferases has been identified, all but one of which contain a conserved catalytic SET domain originally identified in the Drosophila Su(var)3-9, Enhancer of zeste, and Trithorax proteins. Lysine methylation occurs primarily on histones H3 (Lys4, 9, 27, 36, 79) and H4 (Lys20) and has been implicated in both transcriptional activation and silencing (4). Methylation of these lysine residues coordinates the recruitment of chromatin modifying enzymes containing methyl-lysine binding modules such as chromodomains (HP1, PRC1), PHD fingers (BPTF, ING2), tudor domains (53BP1), and WD-40 domains (WDR5) (5-8). The discovery of histone demethylases such as PADI4, LSD1, JMJD1, JMJD2, and JHDM1 has shown that methylation is a reversible epigenetic marker (9).
For Research Use Only. Not For Use In Diagnostic Procedures. Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.